Table 3.
The multivariable OR for NAFLD and fibrosis according to VAI levels
| Men | VAI levels | |||
| Quartile 1 (≤0.87) |
Quartile 2 (0.87–1.45) |
Quartile 3 (1.46–2.49) |
Quartile 4 (>2.49) |
|
| NAFLD | ||||
| Defined by USFLI | ||||
| Model 1 | 1.00 | 2.58 (2.06 to 3.25) | 5.70 (4.56 to 7.12) | 13.69 (10.88 to 17.22) |
| Model 2 | 1.00 | 2.55 (2.01 to 3.23) | 5.83 (4.61 to 7.36) | 14.97 (11.73 to 19.11) |
| Model 3 | 1.00 | 1.30 (0.75 to 2.27) | 1.16 (0.66 to 2.02) | 1.97 (1.12 to 3.47) |
| NAFLD-related fibrosis | ||||
| Defined by NFS | ||||
| Model 1 | 1.00 | 0.60 (0.38 to 0.95) | 0.67 (0.44 to 1.02) | 0.56 (0.37 to 0.84) |
| Model 2 | 1.00 | 0.84 (0.50 to 1.43) | 1.13 (0.69 to 1.86) | 1.22 (0.75 to 1.98) |
| Model 3 | 1.00 | 1.19 (0.77 to 1.83) | 1.96 (0.61 to 1.50) | 1.13 (0.72 to 1.79) |
| By FIB-4 | ||||
| Model 1 | 1.00 | 0.96 (0.67 to 1.40) | 0.74 (0.50 to 1.10) | 0.51 (0.33 to 0.79) |
| Model 2 | 1.00 | 0.98 (0.65 to 1.46) | 0.80 (0.52 to 1.24) | 0.66 (0.41 to 1.06) |
| Model 3 | 1.00 | 1.04 (0.62 to 1.73) | 0.61 (0.34 to 1.09) | 0.63 (0.34 to 1.16) |
| Defined by APRI | ||||
| Model 1 | 1.00 | 0.95 (0.51 to 1.77) | 1.00 (0.54 to 1.84) | 1.54 (0.88 to 2.69) |
| Model 2 | 1.00 | 0.91 (0.46 to 1.71) | 0.97 (0.52 to 1.81) | 1.53 (0.85 to 2.73) |
| Model 3 | 1.00 | 0.97 (0.46 to 2.04) | 0.71 (0.32 to 1.59) | 1.06 (0.50 to 2.22) |
| Women | Quartile 1 (≤0.99) |
Quartile 2 (1.00–1.63) |
Quartile 3 (1.63–2.65) |
Quartile 4 (>2.65) |
| NAFLD | ||||
| Defined by USFLI | ||||
| Model 1 | 1.00 | 3.45 (2.59 to 4.61) | 7.88 (5.98 to 10.38) | 19.98 (15.15 to 26.33) |
| Model 2 | 1.00 | 3.14 (2.34 to 4.21) | 7.31 (5.51 to 9.70) | 20.07 (15.06 to 26.74) |
| Model 3 | 1.00 | 1.73 (0.85 to 3.53) | 2.90 (1.43 to 5.88) | 4.03 (1.98 to 8.20) |
| NAFLD-related fibrosis | ||||
| Defined by NFS | ||||
| Model 1 | 1.00 | 0.95 (0.53 to 1.73) | 0.83 (0.47 to 1.45) | 0.69 (0.40 to 1.19) |
| Model 2 | 1.00 | 0.91 (0.48 to 1.74) | 0.83 (0.45 to 1.53) | 0.79 (0.43 to 1.45) |
| Model 3 | 1.00 | 1.26 (0.43 to 3.71) | 0.66 (0.23 to 1.86) | 0.70 (0.25 to 1.96) |
| By FIB-4 | ||||
| Model 1 | 1.00 | 1.12 (0.58 to 2.17) | 0.58 (0.27 to 1.28) | 0.64 (0.30 to 1.38) |
| Model 2 | 1.00 | 0.84 (0.42 to 1.67) | 0.41 (0.18 to 0.92) | 0.48 (0.22 to 1.07) |
| Model 3 | 1.00 | 0.69 (0.26 to 1.83) | 0.36 (0.11 to 1.11) | 0.33 (0.11 to 1.00) |
| Defined by APRI | ||||
| Model 1 | 1.00 | 1.20 (0.37 to 3.95) | 1.40 (0.44 to 4.42) | 1.20 (0.37 to 3.95) |
| Model 2 | 1.00 | 1.12 (0.33 to 3.73) | 1.23 (0.38 to 4.03) | 1.12 (0.33 to 3.83) |
| Model 3 | 1.00 | 0.83 (0.13 to 5.26) | 0.83 (0.13 to 5.18) | 0.54 (0.08 to 3.61) |
APRI, AST to platelet ratio index; AST, aspartate aminotransferase; FIB-4, fibrosis-4 index; NAFLD, non-alcoholic fatty liver disease; NFS, NAFLD fibrosis score; USFLI, US fatty liver index; VAI, visceral adiposity index.